CONTEXT The SYNERGY trial comparing enoxaparin and unfractionated heparin in high-risk patients with acute coronary syndromes (ACS) showed that enoxaparin was not inferior to unfractionated heparin in reducing death or nonfatal myocardial infarction (MI) at 30 days. OBJECTIVE To evaluate continued risk in this patient cohort through 6-month and 1-year follow-up. DESIGN, SETTING, AND PATIENT...

The use of heparin have increased in the last years in hospitalized both as prophylaxis and therapeutic. One of the encounter complications of heparin especially with unfractionated heparin though it can be seen with Low molecular weight heparin is thrombocytopenia which could be transient non immune or more badly the immune mediated type heparin induced thrombocytopenia (HIT). Heparin-induced ...

Background: At present, no clear evidence has been provided regarding the superiority of various heparin regimens as bridging treatment after heart surgery in patients who need chronic anticoagulation. Objectives: Aim of present pilot investigation was to prospectively compare the safety of weight adjusted enoxaparin and subcutaneous unfractionated heparin in patients undergoing valvular heart ...

The use of heparin have increased in the last years in hospitalized both as prophylaxis and therapeutic. One of the encounter complications of heparin especially with unfractionated heparin though it can be seen with Low molecular weight heparin is thrombocytopenia which could be transient non immune or more badly the immune mediated type heparin induced thrombocytopenia (HIT). Heparin-induced ...

BACKGROUND Lupus anticoagulants prolong clotting times in phospholipid-dependent coagulation tests. Lupus Ratio assays are integrated tests for lupus anticoagulants that may be based on APTT, RVVT or dPT clotting times. If a patient is being treated with unfractionated heparin, however, the heparin prolong clotting times and the diagnosis of lupus anticoagulant is invalidated. Commercial assays...

Generation and inhibition of activated factor IXa was studied in factor XIa-activated plasma containing 4 mmol/L free calcium ions and 20 mumol/L phospholipid (25 mol% phosphatidylserine/75 mol% phosphatidylcholine). Interference of other (activated) clotting factors with the factor IXa activity measurements could be avoided by using a highly specific and sensitive bioassay. Factor IXa generati...

Background—Unfractionated heparin has been the primary anticoagulant therapy for percutaneous coronary intervention for .20 years. Despite the availability of rapid “point of care” testing, little clinical data defining the optimal level of anticoagulation are available. Furthermore, recent reports have advocated the use of low-dose heparin regimens in the absence of large-scale, well-conducted...

BACKGROUND Unfractionated heparin has been the primary anticoagulant therapy for percutaneous coronary intervention for >20 years. Despite the availability of rapid "point of care" testing, little clinical data defining the optimal level of anticoagulation are available. Furthermore, recent reports have advocated the use of low-dose heparin regimens in the absence of large-scale, well-conducted...

Protamine reversal of heparin anticoagulation in patients is occasionally associated with life-threatening acute pulmonary hypertension. In a sheep model, we evaluated the effect on this adverse cardiopulmonary reaction of modifying the type of heparin (low molecular weight heparin compared with unfractionated heparin) and the type of heparin antagonist (polybrene compared with protamine). Prot...

Several low molecular weight (LMW) heparin preparations, including dalteparin, enoxaparin and nadroparin, as well as the heparinoid danaparoid sodium, are approved for use in Australia. LMW heparins are replacing unfractionated heparin for the prevention and treatment of venous thromboembolism and the treatment of non-ST-segment-elevation acute coronary syndromes. The advantages of LMW heparins...